No information provided.
Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.
Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily.
Humatin is indicated for intestinal amebiasis - acute and chronic (NOTE - It is not effective in extraintestinal amebiasis); management of hepatic coma - as adjunctive therapy.
Humatin Capsules, each containing paromomycin sulfate equivalent to 250 mg paromomycin, are supplied as follows
NDC 61570-529-10: Bottles of 100
Store at controlled room temperature 15° - 30°C (59° - 86°F).
Protect from moisture.
Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620. Manufactured by: Caraco Pharmaceutical Laboratories, Ltd., Detroit, MI 48202. Revised: Nov 2001
Included as part of the PRECAUTIONS section.
PRECAUTIONSThe use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken.
The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.
Pediatric UseSee DOSAGE AND ADMINISTRATION section.
Adults and Pediatric Patients: Usual dose - 25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.
Management of Hepatic ComaAdults: Usual dose - 4 g daily in divided doses, given at regular intervals for five to six days.
Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily.
DRUG INTERACTIONSNo information provided.
